Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety
Background: The VOYAGER PAD trial (Vascular Outcomes Study of ASA Along With
Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery …
Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery …
Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial
ES Debus, MR Nehler, N Govsyeyev, RM Bauersachs… - Circulation, 2021 - Am Heart Assoc
Background: Patients with peripheral artery disease requiring lower extremity
revascularization (LER) are at high risk of adverse limb and cardiovascular events. The …
revascularization (LER) are at high risk of adverse limb and cardiovascular events. The …
Reduction in acute limb ischemia with rivaroxaban versus placebo in peripheral artery disease after lower extremity revascularization: insights from VOYAGER PAD
Background: Patients with peripheral artery disease (PAD) are at heightened risk of acute
limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality …
limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality …
Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial
Background Patients with peripheral artery disease (PAD) undergoing lower extremity
revascularization (LER) are at high risk of major adverse limb and cardiovascular events …
revascularization (LER) are at high risk of major adverse limb and cardiovascular events …
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease …
Background Patients with peripheral artery disease (PAD) undergoing a lower-extremity
revascularization are at heightened risk for ischemic cardiac and limb events. Although …
revascularization are at heightened risk for ischemic cardiac and limb events. Although …
Rivaroxaban in peripheral artery disease after revascularization
Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …
revascularization are at high risk for major adverse limb and cardiovascular events. The …
Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial
E Kaplovitch, JW Eikelboom, L Dyal, V Aboyans… - JAMA …, 2021 - jamanetwork.com
Importance Patients with symptomatic lower extremity peripheral artery disease (LE-PAD)
experience an increased risk of major vascular events. There is limited information on what …
experience an increased risk of major vascular events. There is limited information on what …
Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial
F Moll, I Baumgartner, M Jaff… - Journal of …, 2018 - journals.sagepub.com
Purpose: To report a randomized study that investigated the safety (risk of major bleeds) and
potential efficacy of edoxaban, an oral anticoagulant that targets the major components of …
potential efficacy of edoxaban, an oral anticoagulant that targets the major components of …
Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease
WS Jones, I Baumgartner, WR Hiatt, G Heizer… - Circulation, 2017 - Am Heart Assoc
Background: In patients with symptomatic peripheral artery disease with a history of limb
revascularization, the optimal antithrombotic regimen for long-term management is …
revascularization, the optimal antithrombotic regimen for long-term management is …
A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of …
Peripheral artery disease affects> 200 million people worldwide and is associated with
significant limb and cardiovascular morbidity and mortality. Limb revascularization is …
significant limb and cardiovascular morbidity and mortality. Limb revascularization is …
相关搜索
- artery disease extremity revascularization
- artery disease rivaroxaban and aspirin
- artery disease voyager pad
- concomitant clopidogrel rivaroxaban and aspirin
- concomitant clopidogrel extremity revascularization
- extremity revascularization rivaroxaban and aspirin
- extremity revascularization efficacy and safety
- artery disease concomitant clopidogrel
- concomitant clopidogrel efficacy and safety
- artery disease efficacy and safety
- extremity revascularization voyager pad
- surgical revascularization aspirin in patients
- extremity revascularization limb ischemia
- artery disease limb ischemia
- effect of rivaroxaban aspirin in patients
- surgical revascularization effect of rivaroxaban